Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma

Area of Science:

• Oncology
• Immunology
• Vascular Biology

Background:

• Hepatocellular carcinoma (HCC) is a deadly cancer with increasing global incidence.
• Sorafenib, a multikinase inhibitor, is the standard systemic therapy for advanced HCC, primarily targeting vascular endothelial growth factor (VEGF) receptors.
• VEGF's role extends beyond angiogenesis to immunosuppression, affecting dendritic cell maturation and promoting immune-suppressive cells.

Purpose of the Study:

• To explore the dual role of VEGF in HCC, considering both its pro-angiogenic and immunosuppressive functions.
• To investigate the potential challenges and strategies for combining anti-VEGF therapy with immunotherapy in HCC treatment.

Main Methods:

• Review of existing literature on sorafenib, VEGF signaling, and tumor immunology in the context of HCC.
• Analysis of the impact of VEGF inhibition on the tumor microenvironment and immune cell function.
• Exploration of potential synergistic mechanisms and therapeutic combinations.

Main Results:

• Sorafenib's inhibition of VEGF has anti-vascular effects but also impacts the immune system by hindering dendritic cell maturation and promoting immune suppression.
• Potent VEGF inhibition might exacerbate tumor hypoxia, potentially impairing anti-tumor immunity and the efficacy of immunotherapy.
• The interplay between VEGF inhibition, hypoxia, and the immune microenvironment is critical for therapeutic success.

Conclusions:

• Combining anti-VEGF therapy with immunotherapy for HCC may require precise strategies, such as dose titration or co-administration with other immunomodulators.
• Optimizing the tumor microenvironment is crucial for achieving synergy between anti-VEGF agents and immunotherapies in advanced HCC.
• Further research is needed to elucidate the complex interactions and develop effective combination treatments.